| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2927226 | IJC Metabolic & Endocrine | 2015 | 4 Pages |
Abstract
BackgroundBiomarkers play an important role in the diagnosis and risk stratification of patients with ischemic heart disease. Currently, troponin continues as the reference biomarker in acute coronary syndromes. However, there are other biomarkers that have shown additional value in improving sensitivity and prognostic information. Several promising molecules are reviewed, some related to cardiomyocyte structure and others working as inflammatory and renal function markers.ConclusionsAlthough many biomarkers have been shown useful in some studies, further prospective studies are needed to establish their accurate usefulness in routine clinical practice.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
David del Val Martin, Marcelo Sanmartín Fernández, Jose Luís Zamorano Gómez,